Separation Agreement, dated March 31, 2023, by and between Detlef Albrecht and Satsuma Pharmaceuticals, Inc
Exhibit 10.2
This document supersedes any previous version shared with you
SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS +
This Separation Agreement and General Release of Claims (“Separation Agreement”) is entered as of 3/31/2023 (“Effective Date”) into by Detlef Albrecht (“Employee”), and Satsuma, Inc., together with subsidiaries, affiliates (including TriNet Group, Inc.), predecessors and successors (collectively, the “Company”).
2. Employee’s Release of Claims.
1
Detlef Albrecht
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, , IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
BEING AWARE OF SAID CODE SECTION, EMPLOYEE HEREBY EXPRESSLY WAIVES ANY RIGHTS EMPLOYEE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
d) In accordance with the Older Workers Benefit Protection Act of 1990, Employee is informed of the following:
2
Detlef Albrecht
e) Employee understands that this Release shall become effective, irrevocable, and binding upon Employee on the eighth (8th) day after the Effective Date, so long as Employee has not revoked it within the time period and in the manner specified in clause (d)(iv) above. Employee further understands that Employee will not be entitled to any severance payments or benefits under Section 1 above unless Employee executes this Release, and any applicable revocation period hereunder shall have expired
f) Employee acknowledges that that the Company has provided Employee with ADEA disclosure information (under 29 U.S.C. § 626(f)(1)(H)), attached hereto as Exhibit A
3. Employee’s Representations. Employee represents and warrants that:
a) Employee has returned to the Company all Company property in Employee’s possession;
b) Employee is not owed wages, commissions, bonuses or other compensation, other than as set forth in this Separation Agreement;
c) During the course of Employee’s employment, Employee did not sustain any injuries for which Employee might be entitled to compensation pursuant to worker’s compensation law;
d) Employee has not initiated any adversarial proceedings of any kind against the Company or against any other person or entity released herein, nor will Employee do so in the future, except as specifically allowed by this Separation Agreement; and
e) Has carefully read and fully understands all of the provisions of this Separation Agreement and has voluntarily agreed to accept all of the terms contained therein without coercion or pressure from Company.
4. Confidentiality.
a) Employee agrees to keep the fact, terms and amount of this Separation Agreement completely confidential and not hereafter disclose any information concerning this Separation Agreement, provided that Employee may make such disclosures as are required by federal/state taxing authorities or as are necessary for the compliance purposes or as required by judicial action.
b) Nothing in this Separation Agreement shall prevent Employee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful.
5. Severability. In the event any provision of this Release is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.
6. Interpretation; Construction. The headings set forth in this Release are for convenience only and shall not be used in interpreting this Release. Employee acknowledges that Employee has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Release. Either party’s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Release.
3
Detlef Albrecht
7. Governing Law and Venue. This Release will be governed by and construed in accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof.
8. Entire Agreement. This Separation Agreement constitutes the entire agreement of the parties in respect of the subject matters contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral, with the exception of the Employee’s previously executed Proprietary Information and Inventions Assignment Agreement, which shall remain in full force and effect. No waiver, amendment or modification of this Separation Agreement will be effective under any circumstances whatsoever.
9. Miscellaneous. Facsimile or pdf signatures shall have the same force and effectiveness as original signatures. EMPLOYEE HAS READ THIS SEPARATION AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, EMPLOYEE HAS EXECUTED THIS SEPARATION AGREEMENT ON THE DATES SHOWN BELOW.
4
Detlef Albrecht
Please do not sign this document until your last day with the company.
You have until May 15, 2023 (45 days) to review and consider this Agreement and may sign it before that date, if you wish.
COMPANY EMPLOYEE
/s/ John Kollins /s/ Detlef Albrecht
By: John Kollins Date: 3/31/2023
Title: President & Chief Executive Officer
5
Detlef Albrecht
Exhibit A
DECISIONAL UNIT: Reduced number of staff required to support our current business plan and strategy, which calls for continued support of our STS101 program only to the extent necessary to maintain its viability until such time, if any, as we may be able to conclude a strategic transaction.
Job Title | EMPLOYEE AGE | NUMBER IMPACTED | EMPLOYEE AGE | NUMBER NOT IMPACTED |
Chief Medical Officer | 62 | 1 |
| 0 |
Clinical Project Manager | 62 | 1 |
| 0 |
Clinical Trial Associate | 47 | 1 |
| 0 |
Chief Commercial Officer | 55 | 1 |
| 0 |
Director, Clinical Operations | 58 | 1 |
| 0 |
Senior Supply Chain Manager | 61 | 1 |
| 0 |
Quality Assurance Manager | 59 | 1 |
| 0 |
Vice President, Clinical Opera | 61 | 1 |
| 0 |
Medical Device Eng Sr Mgr |
|
| 35 | 1 |
VP, Corporate Controller |
|
| 73 | 1 |
VP of Manufacturing Operations |
|
| 45 | 1 |
Director of Accounting |
|
| 64 | 1 |
VP & Head of Operations |
|
| 44 | 1 |
Sr Dir of QA and Compliance |
|
| 47 | 1 |
Senior Quality Engineer |
|
| 33 | 1 |
Associate Director of Mfg |
|
| 34 | 1 |
Manager of Analytical |
|
| 33 | 1 |
President & Chief Executive Of |
|
| 60 | 1 |
Associate Director of Analytic |
|
| 36 | 1 |
Sr Vice President Head of CMC |
|
| 58 | 1 |
VP & Head of Reg. Affairs |
|
| 46 | 1 |
Trial Master File Manager II |
|
| 39 | 1 |
CFO |
|
| 58 | 1 |
Sr Director of Operations |
|
| 49 | 1 |
|
|
|
|
|
6
Detlef Albrecht